A prospective cohort study of the effect of depot medroxyprogesterone acetate on detection of plasma and cervical HIV-1 in women initiating and continuing antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 4, 2014, Pages 452-456

  Day, Summer ^a   Graham, Susan M ^a,b   Masese, Linnet N ^a   Richardson, Barbra A ^a,c   Kiarie, James N ^b   Jaoko, Walter ^b   Mandaliya, Kishorchandra ^d   Chohan, Vrasha ^a,c   Overbaugh, Julie ^c   Scott McClelland, R ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c Fred Hutchinson Cancer Research Center   (United States)

^d Pathcare Laboratories   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MEDROXYPROGESTERONE ACETATE; VIRUS RNA;

ADULT; ARTICLE; BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; UTERINE CERVIX; VIRUS DETECTION; VIRUS INFECTIVITY; VIRUS SHEDDING; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; CERVIX MUCUS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KENYA; MEDROXYPROGESTERONE ACETATE; RNA, VIRAL;

EID: 84903755625     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000187     Document Type: Article

References (29)

1. UNAIDS. UNAIDS report on the global AIDS epidemic. 2013. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/ gr2013/UNAIDS-Global-Report-2013-en.pdf. Accessed March 04, 2014
2. Reynolds H, Janowitz B, Homan R, et al. The value of contraception to prevent perinatal HIV transmission. Sex Transm Dis. 2006;33:350-356. (Pubitemid 43833021)
3. United Nations Population Division. World Contraceptive Patterns- 2013. Available at: http://www.un.org/en/development/desa/population/publications/ family/contraceptive-wallchart-2013.shtml. Accessed March 04, 2014
4. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;1:19-26
5. Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011;3:77ra29
6. Wang C, McClelland R, Overbaugh J. The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS. 2004;18:205-209. (Pubitemid 38253442)
7. Mostad S, Overbaugh J. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet. 1997;350:922
8. Graham SM, Masese L, Gitau R, et al. Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis. 2010; 202:1538-1542
9. Morrison CS, Demers K, Kwok C, et al. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS. 2010;24:573-582
10. Polis C, Phillips S, Curtis K. Hormonal contraceptive use and female-tomale HIV transmission: a systematic review of the epidemiologic evidence. AIDS. 2013;27:493-505
11. Graham S, Holte S, Peshu N. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS. 2007;21: 501-507
12. Cohen M, Chen Y, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505
13. Neely MN, Benning L, Xu J, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44:38-42. (Pubitemid 46052218)
14. Cu-Uvin S, Caliendo A, Reinert S. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS. 2000;14:415-421. (Pubitemid 30182438)
15. Cu-Uvin S, DeLong A, Venkatesh K, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS. 2010;24:2489-2497
16. Kenya Ministry of Health. Guidelines to Antiretroviral Drug Therapy in Kenya. Nairobi, Kenya: Kenya Ministry of Health; 2005
17. Oyugi J, Byakika-Tusiime JCE. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36: 1100-1102. (Pubitemid 38989377)
18. Graham S, Jalalian-Lechak Z, Shafi J, et al. Antiretroviral treatment interruptions predict female genital shedding of genotypically resistant HIV-1 RNA. J Acquir Immune Defic Syndr. 2012;60:511-518
19. Martin HL, Nyange PM, Richarson BA, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1998;178: 1053-1059. (Pubitemid 28452198)
20. Bracken MB, Hellenbrand KG, Holford TR. Conception delay after oral contraceptive use: the effect of estrogen dose. Fertil Steril. 1990;53:21-27. (Pubitemid 20041310)
21. Pardthaisong T, Gray RH, McDaniel EB. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand. Lancet. 1980;8:509-512
22. Stanback J, Mbonye A, Bekita A. Contraceptive injections by community health workers in Uganda: a nonrandomized community trial. Bull World Health Organ. 2007;85:768-773. (Pubitemid 350082917)
23. Trussell J. Contraceptive efficacy. In: Hatcher R, Trussell J, Nelson AL, et al, eds. Contraceptive Technology, 9th Revised Edition. New York, NY: Ardent Media Inc; 2007:747-826
24. Phillips S, Curtis K, Polis C. Effect of hormonal contraceptive methods on HIV disease progression: a systematic review. AIDS. 2013;27:787-794
25. The World Health Organization. Hormonal contraception and HIV. Technical Statement. 2012. Available at: http://whqlibdoc.who.int/hq/2012/WHO-RHR-12.08- eng.pdf. Accessed May 12, 2013
26. Tseng A, Hills-Nieminen C. Drug interactions between antiretrovirals and hormonal contraceptives. Expert Opin Drug Metab Toxicol. 2013; 9:559-572
27. Butler A, Smith J, Polis C, et al. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS. 2013;27:105-113
28. Jain A. Hormonal contraception and HIV acquisition risk: implications for individual users and public policies. Contraception. 2012;86:645-652
29. Rodriguez M, Reeves M, Caughey A. Evaluating the competing risks of HIV acquisition and maternal mortality in Africa. BJOG. 2012;119: 1067-1073